Medtech leaders prioritize technology and consumers
Findings from a new survey and analysis of earnings calls in the first half of 2020
About the Deloitte Center for Health Solutions

The source for fresh perspectives in health care: The Deloitte Center for Health Solutions (DCHS), part of Deloitte LLP’s Life Sciences and Health Care practice, looks deeper at the biggest industry issues and provides new thinking around complex challenges. Cutting-edge research and thought-provoking analysis give our clients the insights they need to see things differently and address the changing landscape.

Connect

To learn more about the DCHS and our research, please visit www.deloitte.com/centerforhealthsolutions.

Subscribe

To receive email communications, please visit www.deloitte.com/us/LSHC-subscribe.
To subscribe to our blog, please visit https://blogs.deloitte.com/centerforhealthsolutions/.

Engage

Follow us on Twitter at: @DeloitteHealth.
Engage with us on LinkedIn via ConvergeHEALTH by Deloitte.

Patients, payers, and providers all look to technology to help them deliver better outcomes at lower costs. The impact of exponential technology and augmented intelligence isn't confined to the application of care. It also shapes the relationships and market forces that drive the industry. Digital technology is inseparable from health care, and it is also central to new consumer expectations for how they will manage and receive that care.

Deloitte is a leader in life sciences, digital technology, and in the ways they intersect. Our solutions help life sciences companies reinvent strategies that embrace change and implementations that redefine it. Contact the authors for more information.
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive summary</td>
<td>2</td>
</tr>
<tr>
<td>Advances in technology, the top issue facing medtech</td>
<td>4</td>
</tr>
<tr>
<td>Cyber and digital transformation of functions rise in list of priorities</td>
<td>5</td>
</tr>
<tr>
<td>How do medtech companies expect future of health developments to impact their business?</td>
<td>8</td>
</tr>
<tr>
<td>Companies are investing in digital capabilities, but none rate themselves as digitally mature</td>
<td>10</td>
</tr>
<tr>
<td>Long-term goals and the COVID-19 impact: How can companies reboot and recover?</td>
<td>12</td>
</tr>
<tr>
<td>Implications</td>
<td>13</td>
</tr>
<tr>
<td>Endnotes</td>
<td>14</td>
</tr>
</tbody>
</table>
Executive summary

MEDTECH COMPANIES ARE continuously working toward bringing innovative and breakthrough products to global markets. In our survey, we expected senior executives to highlight innovation as a major strategic focus and we found this held true—innovation, fueled by technology, is important today and will assume even greater importance in the future. When we asked about new types of offerings, responses revealed some gaps between how important some of the new technologies will be and how well-prepared companies said they felt to drive impact. To be successful in future, medtech companies should integrate features in their offerings, including digital well-being, virtual care, and remote monitoring. They should also invest in technology to transform their businesses and become more efficient and effective in the market.

COVID-19 has affected multiple aspects of medical technology—on the positive side, it has created demand for rapid and accurate tests and an adequate supply of personal protective equipment. The shift of some health care to virtual is an exciting opportunity. However, delayed nonurgent care has created some headwinds for the industry, and the broader economic, trade, and supply chain issues accompanying the pandemic may be felt for some time.

This article provides insights from two sources: a survey we fielded in March and April 2020, during the COVID-19 pandemic, and text analysis of 39 medtech companies’ quarterly earnings statements in the last quarter of 2019 and first quarter of 2020 (for details, see sidebar, “Methodology”).

Our survey found that:

- A huge majority (88%) of respondents rated advances in technology as a top challenge, followed by policy and regulatory activity, and changes in consumer attitudes, behaviors, and spending (63%).

- Half (50%) of the executives rated transformation of functions using digital and information technologies, cyber readiness, and economic issues as their highest priorities. Looking ahead, 69% of them said cyber readiness will be their highest priority in the next five years—signaling the need to balance digital transformation opportunities with risk preparedness. Half or more of respondents also flagged transformation of functions using digital and information technologies (56%), and economic issues (50%) as areas of focus.

- Executives think they are most prepared to address emerging opportunities around customized treatments (81%), curative therapies (69%), and digital therapeutics (63%); only 38% said they are prepared for developments in nonpharmacological interventions—nontraditional technologies such as robotics, nanotechnology, or tissue engineering.

- Even though leveraging digital technologies is an important strategic priority, none of the
companies rated themselves as digitally mature.

As economies and the health care industry start to recover, investments into emerging technologies (such as robotics, AR/VR) will likely gain even greater prominence—both in Medtech products and in transforming aspects of the business. The future of health (especially virtual care) and the future of work (especially virtual work) are likely to arrive sooner than we would have predicted even last year.

**METHODOLOGY**

Between March and April 2020, the Deloitte Center for Health Solutions surveyed medtech company leaders to understand their strategic priorities and the risks and challenges the industry faces. Respondents to the survey included individuals in the following roles: chief executive officer (CEO), chief operating officer (COO), chief commercial officer (CCO), and EVPs/VPs of business/corporate development of 16 medtech companies.

In addition, we analyzed quarterly earnings statements from 39 of the largest medtech companies. The analysis was based on relevance analysis of keyword/ontology employing natural language processing to determine which themes/issues the industry thinks could have an impact on operations in the current environment.
Advances in technology, the top issue facing medtech

CLOSE TO 90% of respondents rated advances in technology as the top issue. This makes sense given that medtech companies are in the business of technology as a product offering, but also may be seeing opportunities to transform aspects of their business with digital investments.

The next most common issues cited were changing consumer attitudes and spending behavior and policy and regulatory issues (63%). Respondents rated policies affecting supply chain, privacy and data security, and tax as equally important. Policy and regulatory changes can create new opportunities—for example new payment models in Medicare—but they can also slow down innovation or make compliance more costly.1 More than half of the respondents cited cyber and business model disruptions as top issues. A focus on innovation may call for different approaches to payment, partnerships, and commercial models, which is consistent with what we found in a recent report, Winning in the future of medtech.2 In the future, medtech companies are likely to change dramatically. The scope for collaborations and partnerships to address consumers’ demands is likely to increase. One approach that medtech companies can consider is partnering with consumer technology companies, which can help them develop offerings that keep people well (e.g., for devices for tracking biometric information) and demonstrate value to purchasers.

FIGURE 1
Adoption of advanced technology, policy and regulatory compliance, and understanding consumer behavior are top issues impacting medtech companies

<table>
<thead>
<tr>
<th>Issue</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advances in technology</td>
<td>88%</td>
</tr>
<tr>
<td>Policy and regulatory activity</td>
<td>63%</td>
</tr>
<tr>
<td>Changes in consumer attitude, behaviors, and spending</td>
<td>63%</td>
</tr>
<tr>
<td>Cybersecurity threats</td>
<td>56%</td>
</tr>
<tr>
<td>Business model disruptions</td>
<td>56%</td>
</tr>
</tbody>
</table>

Source: Deloitte analysis.
Cyber and digital transformation of functions rise in list of priorities

When we asked respondents to rank their current strategic priorities, they chose cyber and transformation of functions using digital. Cyber rises from a top strategic priority for 50% of companies right now to a top priority for 69% in five years. Respondents also expect R&D, global markets, and policy and regulatory to be more important priorities in five years than they are today.
FIGURE 2

Over the next five years, cyber readiness, transformation of functions using digital and information technologies, and economic activity will remain companies’ top strategic priorities.

Note: Graph represents % of respondents who said “5—High priority” today vs. next five years.
Source: Deloitte analysis.
FIGURE 3

Text analytics of investor statements in the first half of 2020 show that restructuring and diagnostics are top of mind

Q4 2019

Q1 2020

Note: Word cloud includes top 50 based on relevance from the analysis and investor calls of 39 medtech companies.
Source: Deloitte analysis.

Our analysis of the text analysis of investor meeting transcripts in the last quarter of 2019 and first quarter of 2020 showed a strong focus in both the periods on diagnostics as an area of strategic focus. Between the two periods, the words “consumer” and “elective procedures” gained salience—likely reflecting the COVID-19 pandemic. The words “restructuring” and “earnings per share” declined in prominence between the two periods.

The research from text analytics points to an increased focus toward emerging and novel technologies, new business models, and the economic impact companies are faced with due to the pandemic. This is consistent with our survey findings.
How do medtech companies expect future of health developments to impact their business?

For medtech companies, as their survey responses and the text analytics show, the key to future growth will likely be understanding consumers’ needs, harnessing data, keeping people well, and taking advantages of insights and innovation coming from new technologies. Companies can win in the new health economy if they offer high value products and services—not only those that have the latest technology and clinical impact, but also that can be positioned to improve total cost of care. These perspectives are all consistent with our vision for the future of health.

Our survey asked respondents to consider five statements that align with our future of health perspective for life sciences companies—some of which are threats to pharma companies and opportunities for medical technology companies. We asked about:

- Curative therapies where companies assess new treatment regimen and develop a better understanding of cure. For this, companies may need to adopt different business models.
- Nonpharmacological interventions that include adoption of sophisticated and nontraditional medical technologies. This could bring precise medical intervention enabled by robotics, nanotechnology, or tissue engineering.
- Prevention and early detection to reduce prevalence of certain diseases by advancements in new technologies, and help consumers with early detection.
- Customized treatments that include personalized treatments, utilizing patient data to provide custom solutions.
- Digital therapeutics that could help advance transition to more care outside the hospital setting.

Survey respondents rated nonpharmacological interventions (94%) and curative therapies and customized treatments (75%) as most impactful.

Are they prepared to develop solutions and adapt to these changes? Medtech leaders rated their companies as well prepared to deal with growing demand for customized treatments, curative therapies, and digital therapeutics. The biggest gap between impact and preparedness was for
nonpharmacological intervention (only 38% felt they were well prepared; a 56% difference in impact versus preparedness).

Digital therapeutics is gaining traction with a shift in focus from treatment to prevention and higher use of real-time data for greater patient control. As the health sector transitions from a focus on acute intervention to one centered around prevention and wellness, these technologies will likely evolve. There is an increase in focus on technologies that track real-time data, and investment in artificial intelligence–based wellness coaching that could help enable behavior change, avoiding the need for surgery or hospitalization altogether.4
Companies are investing in digital capabilities, but none rate themselves as digitally mature

Opportunities for digital transformation are available throughout medtech companies’ business, from business operations such as production and enabling functions to engagement with patients, physicians, health systems, and payers to developing new products and services. Realizing each opportunity can require the capabilities of a digitally maturing organization, including an overall strategy, culture of collaboration and experimentation, and supportive leadership. Digitally maturing companies differ from those in the earlier stages of digital maturity in the way they apply digital, scale learnings, collaborate, and facilitate change.6

FIGURE 4
Over the next 10 years, respondents expect nonpharmacological interventions to have a high impact on the industry

<table>
<thead>
<tr>
<th>Nonpharmacological intervention</th>
<th>No impact at all</th>
<th>Little impact</th>
<th>Moderate impact</th>
<th>A lot of impact</th>
<th>Very high impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Customized treatments</td>
<td>6%</td>
<td>25%</td>
<td>44%</td>
<td>31%</td>
<td></td>
</tr>
<tr>
<td>Prevention and early detection</td>
<td>6%</td>
<td>25%</td>
<td>50%</td>
<td>19%</td>
<td></td>
</tr>
<tr>
<td>Digital therapeutics</td>
<td>6%</td>
<td>31%</td>
<td>50%</td>
<td>13%</td>
<td></td>
</tr>
<tr>
<td>Curative therapies</td>
<td>6%</td>
<td>19%</td>
<td>63%</td>
<td>13%</td>
<td></td>
</tr>
</tbody>
</table>

Note: There were no responses for “No impact at all”.
Source: Deloitte analysis.
Companies believe that transforming functions using digital technologies will be of high strategic priority in the next five years. Less than half of the medtech companies responded that they are using digital technologies and capabilities to improve processes (44%). Surveyed medtech leaders reported that the key objectives for their digital investments are to reduce costs (31%), gain insights into execution of business strategy (25%), and increase demand for products (25%).

Digital investment can help companies have a cost-effective and optimized way of executing business strategies. Going digital can help companies deal with rapidly changing technologies and improve the research and development process by strengthening the pipeline.
Long-term goals and the COVID-19 impact: How can companies reboot and recover?

In unstructured comments to the survey, executives flagged economic challenges arising from COVID-19 that may impact their long-term goals. The pandemic has created headwinds around reduced volume of services due to postponement of nonurgent care, and created some supply chain issues. They also mentioned general economic issues as an area of concern.

Some of the comments they made include:

• “COVID-19 will be a major reason to slow down growth this year.” —EVP, medtech company

• “The first challenge is the outbreak of coronavirus all over the globe. Secondly, it is mainly about the old school vs. the new technologies that are coming up that pose a challenge. And the final challenge we see is how to map demand with supply.” —EVP, medtech company

• “Poor analysis of future requirements for our investment. Coping with changing procedures due to COVID-19.” —COO, medtech company
Implications

EMBRACE THE FUTURE of health. Many in the medtech industry are steering toward digital adoption, technological transformation, changing consumer attitudes, and business model disruptions. To achieve this, companies should consider new capabilities to win in the future of health. Being prepared with consumer-centric product portfolios, and an operating and business model that supports this, can be key to companies. Medtech companies should also consider building platforms to make sense of all the available data. Companies should also see the need to forge partnerships with hospitals to collect data on unmet needs to build nonpharmacological interventions. Medtech companies should consider what role they would like to play in the future ecosystem: data and platform provider, well-being and care delivery organization, care enabler, or elements of all three. This change in strategic focus may require leaders to identify their company’s relative strength, revisit their business strategy to cater to changing consumer demand, and identify ways to fill the gaps.

Define strategic goals in the context of new entrants, business models, and opportunities. Medtech companies are facing new competitive threats. Their strategies should answer fundamental questions of whether or not companies want to be product or solution companies; this then leads to questions about whether they want to be in the hardware or software business moving forward. Once they decide this, they should figure out where they will get the capabilities (partnerships) and what the business model (payment) might look like. Companies are forming traditional partnerships that have focused on hardware development and partnering with consumer technology companies to be able to work on software/platforms as well.

Virtual may be a way to go. One feature of COVID-19 has been the rapid adoption by consumers and physicians of virtual care. One might expect sustained interest in virtual care, home care, and remote monitoring services. Medtech companies might want to invest in remote monitoring solutions to improve remote access to patients, to help enable the transition to more care outside of the hospital and shift the emphasis toward prevention and maintaining well-being.

Consider digital investments to save money, gain insight into business operations, and accelerate competitive opportunities. Medtech companies can benefit greatly by digitization—scenarios such as a network of devices, machines, and other items embedded with sensors enable interconnectivity and exchange of data—and can help connect manufacturers with suppliers. Logistics and distribution are also benefitted in avoiding costs of physical product damages, deterioration during distribution, and consequences faced due to widespread counterfeiting in the market.

Prepare for and address, especially cyber and economic risks, but also policy and regulatory risks. With increased digitization, medtech companies should be prepared to handle and mitigate cyber risks. The growth of connected medical devices renders medical devices to be susceptible to cybersecurity attacks. In addition, companies should stay prepared for change in any laws and regulations that could potentially lead to losses to business.
Endnotes


2. Ibid.


4. Ibid.


Acknowledgements

Project team: Madhushree Wagh and Jessica Overman assisted with the quantitative analysis and writing of the report. Alok Ranjan and Shruti Panda offered their expertise and support on the text analysis for this research. Sonal Shah from the team helped review the paper.

This research would not have been possible without the support from Deloitte’s Life Sciences leaders: Bill Murray, Pedro Arboleda, and Douglas Billings. The authors would also like to thank Ramani Moses, Laura DeSimio, and the many others who contributed to the success of this project.
About the authors

Glenn Snyder   |   gsnyder@deloitte.com
Glenn Snyder is a principal with Deloitte Consulting and leads Deloitte LLP's Medical Technology practice with more than 25 years of experience in medical technology, biotech, and specialty pharmaceuticals. He helps clients grow through organic and inorganic means by entering new geographic markets and expanding into new product/service areas. Snyder also helps clients improve brand/commercial effectiveness by articulating product economic value, applying innovative pricing, updating the commercial model, and rationalizing distribution networks.

Bushra Naaz   |   bnaaz@deloitte.com
Bushra Naaz is an executive manager with the Deloitte Center for Health Solutions. She holds 14 years of experience in consulting, strategy, and business research in the life sciences and health care industry. At Deloitte, her research focuses on perspectives that allow clients to anticipate, prepare for, and respond to what's coming next. Naaz holds a postgraduate business management diploma in international business from the Symbiosis Institute of Management Studies, Pune, and a bachelor's degree in science.
Contact us

*Our insights can help you take advantage of change. If you're looking for fresh ideas to address your challenges, we should talk.*

Industry leadership

**Glenn Snyder**  
Principal | Deloitte Consulting LLP  
+1 415 699 4469 | gsnyder@deloitte.com

As the lead of Deloitte LLP’s Medical Technology practice, Glenn Snyder helps clients grow through organic and inorganic means by entering new geographic markets and expanding into new product/service areas. Snyder also helps clients improve brand/commercial effectiveness by articulating product economic value, applying innovative pricing, updating the commercial model, and rationalizing distribution networks.

**The Deloitte Center for Health Solutions**

**Sarah Thomas, MS**  
Managing director | The Deloitte Center for Health Solutions | Deloitte Services LP  
+1 202 220 2749 | sarthomas@deloitte.com

Sarah Thomas is the managing director of the Deloitte Center for Health Solutions, part of Deloitte LLP’s Life Sciences and Health Care practice. As the leader of the center, she drives the research agenda to inform stakeholders across the health care landscape about key trends and issues facing the industry. Thomas has more than 13 years of government experience and has deep experience in public policy, with a focus on Medicare payment policy.
Deloitte Insights


Follow @DeloitteInsight

Deloitte Insights contributors
Editorial: Ramani Moses, Hannah Bachman, and Nairita Gangopadhyay
Creative: Sanaa Saifi, Sylvia Yoon Chang, and Victoria Lee
Promotion: Ankana Chakraborty
Cover artwork: Stuart Briers

About Deloitte Insights
Deloitte Insights publishes original articles, reports and periodicals that provide insights for businesses, the public sector and NGOs. Our goal is to draw upon research and experience from throughout our professional services organization, and that of coauthors in academia and business, to advance the conversation on a broad spectrum of topics of interest to executives and government leaders.

Deloitte Insights is an imprint of Deloitte Development LLC.

About this publication
This publication contains general information only, and none of Deloitte Touche Tohmatsu Limited, its member firms, or its and their affiliates are, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your finances or your business. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser.

None of Deloitte Touche Tohmatsu Limited, its member firms, or its and their respective affiliates shall be responsible for any loss whatsoever sustained by any person who relies on this publication.

About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

Copyright © 2020 Deloitte Development LLC. All rights reserved.
Member of Deloitte Touche Tohmatsu Limited